SureTrader
Home > Boards > US OTC > Medical - Drugs > Innovation Pharmaceuticals Inc. (IPIX)

How about the wording in the CDA agreement

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
djs7 Member Profile
 
Followed By 4
Posts 399
Boards Moderated 0
Alias Born 08/29/14
160x600 placeholder
Amended Statement of Ownership (sc 13g/a) "Edgar (US Regulatory)" - 1/11/2018 4:35:53 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 12/27/2017 3:08:40 PM
Prospectus Filed Pursuant to Rule 424(b)(2) (424b2) "Edgar (US Regulatory)" - 11/13/2017 10:03:05 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 11/8/2017 4:04:57 PM
Notice of Effectiveness (effect) "Edgar (US Regulatory)" - 9/22/2017 6:02:17 AM
Securities Registration Statement (simplified Form) (s-3) "Edgar (US Regulatory)" - 9/11/2017 12:47:10 PM
Annual Report (10-k) "Edgar (US Regulatory)" - 9/11/2017 6:04:38 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 9/11/2017 6:04:37 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/6/2017 6:27:18 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/6/2017 6:24:45 PM
Initial Statement of Beneficial Ownership (3) "Edgar (US Regulatory)" - 8/8/2017 4:18:08 PM
Annual Statement of Changes in Beneficial Ownership (5) "Edgar (US Regulatory)" - 8/8/2017 4:17:33 PM
Annual Statement of Changes in Beneficial Ownership (5) "Edgar (US Regulatory)" - 8/8/2017 4:17:00 PM
Annual Statement of Changes in Beneficial Ownership (5) "Edgar (US Regulatory)" - 8/8/2017 4:16:36 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/13/2017 4:04:10 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/7/2017 4:19:05 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 5/9/2017 4:09:09 PM
Amended Statement of Ownership (sc 13g/a) "Edgar (US Regulatory)" - 4/28/2017 12:50:45 PM
Bahamas Development Corp. (OTC Pink: BDCI) $2.4 Million in Sales and 10% Quarterly Growth – Issues Guidance "InvestorsHub NewsWire" - 4/17/2017 7:03:27 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 3/31/2017 4:25:24 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 3/29/2017 4:13:08 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 3/27/2017 11:29:27 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 2/16/2017 7:01:38 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 2/9/2017 4:04:17 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 2/9/2017 9:39:24 AM
djs7   Friday, 01/12/18 03:45:06 PM
Re: Rdunn88 post# 212643
Post # of 213555 
How about the wording in the CDA agreement that could say

"At any time, the interested parties may request a delay or postponement of the interim analysis
while intermittent case reports and analysis are shared from the sponsor IPIX."


As for the 2Q interim analysis, remember the trial originally had a completion date of July 2017. It did not finish til end of December 2017. The delays in enrollment may have pushed an intended Q2 interim analysis to Q3. By such time, a majority of patients had completed at least 6 weeks therapy.


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist